This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keating, N. L. Articles by Smith, M. R. Search for Related Content PubMed PubMed Citation Articles by Keating, N. L. Articles by Smith, M. R. Social Bookmarking                            What's this?

Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

Nancy L. Keating, A. James O'Malley, Matthew R. Smith

From the Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital; the Department of Health Care Policy, Harvard Medical School; and the Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA

Address reprint requests to Nancy L. Keating, MD, MPH, Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115; e-mail: keating{at}hcp.med.harvard.edu

PURPOSE: Androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist is associated with increased fat mass and insulin resistance in men with prostate cancer, but the risk of obesity-related disease during treatment has not been well studied. We assessed whether androgen deprivation therapy is associated with an increased incidence of diabetes and cardiovascular disease.

PATIENTS AND METHODS: Observational study of a population-based cohort of 73,196 fee-for-service Medicare enrollees age 66 years or older who were diagnosed with locoregional prostate cancer during 1992 to 1999 and observed through 2001. We used Cox proportional hazards models to assess whether treatment with GnRH agonists or orchiectomy was associated with diabetes, coronary heart disease, myocardial infarction, and sudden cardiac death.

RESULTS: More than one third of men received a GnRH agonist during follow-up. GnRH agonist use was associated with increased risk of incident diabetes (adjusted hazard ratio [HR], 1.44; P < .001), coronary heart disease (adjusted HR, 1.16; P < .001), myocardial infarction (adjusted HR, 1.11; P = .03), and sudden cardiac death (adjusted HR, 1.16; P = .004). Men treated with orchiectomy were more likely to develop diabetes (adjusted HR, 1.34; P < .001) but not coronary heart disease, myocardial infarction, or sudden cardiac death (all P > .20).

CONCLUSION: GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease. The benefits of GnRH agonist treatment should be weighed against these potential risks. Additional research is needed to identify populations of men at highest risk of treatment-related complications and to develop strategies to prevent treatment-related diabetes and cardiovascular disease.

Supported by the Prostate Cancer Specialized Program of Research Excellence (SPORE) of the National Cancer Institute (Grant No. P50CA90381), and the W. Bradford Ingalls Charitable Foundation. The funder had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. J. Karnes, T. Hatano, M. L. Blute, and R. P. Myers Radical Prostatectomy for High-risk Prostate Cancer Jpn. J. Clin. Oncol., October 19, 2009; (2009) hyp130v1. [Abstract] [Full Text] [PDF]

				M. R. Cooperberg, S. Hinotsu, M. Namiki, K. Ito, J. Broering, P. R. Carroll, and H. Akaza Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy J. Clin. Oncol., September 10, 2009; 27(26): 4306 - 4313. [Abstract] [Full Text] [PDF]

				M. A. Uhlman, J. W. Moul, P. Tang, D. A. Stackhouse, and L. Sun Review: Risk stratification in the hormonal treatment of patients with prostate cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 79 - 94. [Abstract] [PDF]

				A. M. Traish, F. Saad, R. J. Feeley, and A. Guay The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease J Androl, September 1, 2009; 30(5): 477 - 494. [Abstract] [Full Text] [PDF]

				A. Nanda, M.-H. Chen, M. H. Braccioforte, B. J. Moran, and A. V. D'Amico Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease-Induced Congestive Heart Failure or Myocardial Infarction JAMA, August 26, 2009; 302(8): 866 - 873. [Abstract] [Full Text] [PDF]

				S. M.H. Alibhai, M. Duong-Hua, R. Sutradhar, N. E. Fleshner, P. Warde, A. M. Cheung, and L. F. Paszat Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes J. Clin. Oncol., July 20, 2009; 27(21): 3452 - 3458. [Abstract] [Full Text] [PDF]

				W. Dale "Staging the Aging" When Considering Androgen Deprivation Therapy for Older Men With Prostate Cancer J. Clin. Oncol., July 20, 2009; 27(21): 3420 - 3422. [Full Text] [PDF]

				M. Bolla, T. M. de Reijke, G. Van Tienhoven, A. C.M. Van den Bergh, J. Oddens, P. M.P. Poortmans, E. Gez, P. Kil, A. Akdas, G. Soete, et al. Duration of Androgen Suppression in the Treatment of Prostate Cancer N. Engl. J. Med., June 11, 2009; 360(24): 2516 - 2527. [Abstract] [Full Text] [PDF]

				E. J. Giltay and L. J. G. Gooren Potential Side Effects of Androgen Deprivation Treatment in Sex Offenders J Am Acad Psychiatry Law, March 1, 2009; 37(1): 53 - 58. [Abstract] [Full Text] [PDF]

				T H. Jones Late onset hypogonadism BMJ, February 13, 2009; 338(feb13_1): b352 - b352. [Full Text]

				B. A. Inman, J. L. St. Sauver, D. J. Jacobson, M. E. McGree, A. Nehra, M. M. Lieber, V. L. Roger, and S. J. Jacobsen A Population-Based, Longitudinal Study of Erectile Dysfunction and Future Coronary Artery Disease Mayo Clin. Proc., February 1, 2009; 84(2): 108 - 113. [Abstract] [Full Text] [PDF]

				J. A. Efstathiou, K. Bae, W. U. Shipley, G. E. Hanks, M. V. Pilepich, H. M. Sandler, and M. R. Smith Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31 J. Clin. Oncol., January 1, 2009; 27(1): 92 - 99. [Abstract] [Full Text] [PDF]

				Y.-N. Wong, S. Freedland, B. Egleston, G. Hudes, J. S. Schwartz, and K. Armstrong Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer J. Clin. Oncol., January 1, 2009; 27(1): 100 - 105. [Abstract] [Full Text] [PDF]

				P. J. Saylor and M. R. Smith Prostate Cancer Survivorship: Metabolic Complications of Androgen Deprivation Therapy ASCO Educational Book, January 1, 2009; 2009(1): 263 - 268. [Abstract] [Full Text] [PDF]

				J. E. Montie, M. A. Carducci, and D. A. Kuban Perspectives on the Management of Localized Prostate Cancer: Focus on Radiotherapy ASCO Educational Book, January 1, 2009; 2009(1): 270 - 274. [Abstract] [Full Text] [PDF]

				J. L Ockrim and P. D Abel Long term androgen deprivation therapy in prostate cancer BMJ, September 22, 2008; 337(sep22_1): a1361 - a1361. [Full Text]

				M. R. Smith, K. Bae, J. A. Efstathiou, G. E. Hanks, M. V. Pilepich, H. M. Sandler, and W. U. Shipley Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92-02 J. Clin. Oncol., September 10, 2008; 26(26): 4333 - 4339. [Abstract] [Full Text] [PDF]

				S. Basaria Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth J Androl, September 1, 2008; 29(5): 534 - 539. [Abstract] [Full Text] [PDF]

				G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, and S.-L. Yao Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer JAMA, July 9, 2008; 300(2): 173 - 181. [Abstract] [Full Text] [PDF]

				M. D. Michaelson, S. E. Cotter, P. C. Gargollo, A. L. Zietman, D. M. Dahl, and M. R. Smith Management of Complications of Prostate Cancer Treatment CA Cancer J Clin, July 1, 2008; 58(4): 196 - 213. [Abstract] [Full Text] [PDF]

				M. F. McEntee, C. Ziegler, D. Reel, K. Tomer, A. Shoieb, M. Ray, X. Li, N. Neilsen, F. B. Lih, D. O'Rourke, et al. Dietary n-3 Polyunsaturated Fatty Acids Enhance Hormone Ablation Therapy in Androgen-Dependent Prostate Cancer Am. J. Pathol., July 1, 2008; 173(1): 229 - 241. [Abstract] [Full Text] [PDF]

				S. Shahani, M. Braga-Basaria, and S. Basaria Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2042 - 2049. [Abstract] [Full Text] [PDF]

				M. R. Smith, S. B. Malkowicz, F. Chu, J. Forrest, P. Sieber, K. G. Barnette, D. Rodriquez, and M. S. Steiner Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study J. Clin. Oncol., April 10, 2008; 26(11): 1824 - 1829. [Abstract] [Full Text] [PDF]

				T. H. van der Kwast, L. Collette, and M. Bolla In Reply: J. Clin. Oncol., March 10, 2008; 26(8): 1392 - 1393. [Full Text] [PDF]

				A. V. D'Amico, M.-H. Chen, A. A. Renshaw, M. Loffredo, and P. W. Kantoff Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial JAMA, January 23, 2008; 299(3): 289 - 295. [Abstract] [Full Text] [PDF]

				V. Venkateswaran, A. Q. Haddad, N. E. Fleshner, R. Fan, L. M. Sugar, R. Nam, L. H. Klotz, and M. Pollak Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts J Natl Cancer Inst, December 5, 2007; 99(23): 1793 - 1800. [Abstract] [Full Text] [PDF]

				C. S. Saigal Moving Beyond Guidelines to Improve the Quality of Care for Men With Prostate Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5348 - 5349. [Full Text] [PDF]

				C. Nieder, A. Pawinski, N. H. Andratschke, and M. Molls Does Prophylactic Breast Irradiation in Patients With Prostate Cancer Influence Cardiac Toxicity? J Natl Cancer Inst, November 7, 2007; 99(21): 1646 - 1647. [Full Text] [PDF]

				M. A. Yialamas, A. A. Dwyer, E. Hanley, H. Lee, N. Pitteloud, and F. J. Hayes Acute Sex Steroid Withdrawal Reduces Insulin Sensitivity in Healthy Men with Idiopathic Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4254 - 4259. [Abstract] [Full Text] [PDF]

				H. K. Tsai, A. V. D'Amico, N. Sadetsky, M.-H. Chen, and P. R. Carroll Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality J Natl Cancer Inst, October 17, 2007; 99(20): 1516 - 1524. [Abstract] [Full Text] [PDF]

				J. Seidenfeld, D. J. Samson, and P. C. Albertsen Competing Risks for Patients With Localized Prostate Cancer J Natl Cancer Inst, October 17, 2007; 99(20): 1498 - 1499. [Full Text] [PDF]

				M. Zitzmann and E. Nieschlag Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3844 - 3853. [Abstract] [Full Text] [PDF]

				M. D. Michaelson and M. R. Smith In Reply J. Clin. Oncol., August 1, 2007; 25(22): 3385 - 3386. [Full Text] [PDF]

				M. Montano, J. N. Flanagan, L. Jiang, P. Sebastiani, M. Rarick, N. K. LeBrasseur, C. A. Morris, R. Jasuja, and S. Bhasin Transcriptional Profiling of Testosterone-Regulated Genes in the Skeletal Muscle of Human Immunodeficiency Virus-Infected Men Experiencing Weight Loss J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2793 - 2802. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, J. W. Denham, J. Crook, M.-H. Chen, S. Z. Goldhaber, D. S. Lamb, D. Joseph, K.-H. Tai, S. Malone, C. Ludgate, et al. Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions J. Clin. Oncol., June 10, 2007; 25(17): 2420 - 2425. [Abstract] [Full Text] [PDF]

				F. H Schroder Early versus delayed endocrine therapy for prostate cancer Endocr. Relat. Cancer, March 1, 2007; 14(1): 1 - 11. [Abstract] [Full Text] [PDF]

				A. V. D'Amico Toward the Optimal Use of Androgen Suppression Therapy in the Radiotherapeutic Management of Prostate Cancer J. Clin. Oncol., January 1, 2007; 25(1): 8 - 9. [Full Text] [PDF]

				Diabetes and Heart Disease in Men Who Receive Androgen-Deprivation Therapy Journal Watch Oncology and Hematology, October 11, 2006; 2006(1011): 2 - 2. [Full Text]